UNC0 Stock Overview
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for UNC0 from our risk checks.
UCB SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €60.50 |
52 Week High | €62.50 |
52 Week Low | €31.80 |
Beta | 0.38 |
1 Month Change | 3.42% |
3 Month Change | 30.39% |
1 Year Change | 44.74% |
3 Year Change | 57.98% |
5 Year Change | n/a |
Change since IPO | 54.49% |
Recent News & Updates
Recent updates
Shareholder Returns
UNC0 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0.8% | 5.8% | 0.6% |
1Y | 44.7% | -17.7% | 5.4% |
Return vs Industry: UNC0 exceeded the German Pharmaceuticals industry which returned -17.5% over the past year.
Return vs Market: UNC0 exceeded the German Market which returned 7.3% over the past year.
Price Volatility
UNC0 volatility | |
---|---|
UNC0 Average Weekly Movement | 4.5% |
Pharmaceuticals Industry Average Movement | 5.6% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: UNC0's share price has been volatile over the past 3 months.
Volatility Over Time: UNC0's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1925 | 8,767 | Jean-Christophe Tellier | www.ucb.com |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome.
UCB SA Fundamentals Summary
UNC0 fundamental statistics | |
---|---|
Market cap | €23.05b |
Earnings (TTM) | €343.00m |
Revenue (TTM) | €5.18b |
67.2x
P/E Ratio4.4x
P/S RatioIs UNC0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
UNC0 income statement (TTM) | |
---|---|
Revenue | €5.18b |
Cost of Revenue | €1.71b |
Gross Profit | €3.48b |
Other Expenses | €3.13b |
Earnings | €343.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
Earnings per share (EPS) | 1.81 |
Gross Margin | 67.06% |
Net Profit Margin | 6.62% |
Debt/Equity Ratio | 32.1% |
How did UNC0 perform over the long term?
See historical performance and comparison